Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.08
+2.9%		$0.94
$0.74
▼
$1.81
$33.96M0.01148,040 shs159,002 shs
Imunon, Inc. stock logo
IMNN
Imunon
$1.66
+4.4%		$1.73
$1.47
▼
$6.42
$8.92M1.9785,224 shs84,690 shs
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$30.93
-7.6%		$23.01
$15.10
▼
$909.98
$34.05M1.3634,781 shs17,408 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$2.48
+1.6%		$3.63
$2.23
▼
$16.25
$35.28M1.6366,995 shs34,652 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
+2.86%0.00%+25.58%-8.47%-39.66%
Imunon, Inc. stock logo
IMNN
Imunon
+4.40%+5.06%+9.93%-27.83%-73.86%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-7.62%-6.02%+73.28%+34.48%-90.21%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
+1.64%-5.34%-30.14%-45.37%-55.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.08
+2.9%		$0.94
$0.74
▼
$1.81
$33.96M0.01148,040 shs159,002 shs
Imunon, Inc. stock logo
IMNN
Imunon
$1.66
+4.4%		$1.73
$1.47
▼
$6.42
$8.92M1.9785,224 shs84,690 shs
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$30.93
-7.6%		$23.01
$15.10
▼
$909.98
$34.05M1.3634,781 shs17,408 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$2.48
+1.6%		$3.63
$2.23
▼
$16.25
$35.28M1.6366,995 shs34,652 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
+2.86%0.00%+25.58%-8.47%-39.66%
Imunon, Inc. stock logo
IMNN
Imunon
+4.40%+5.06%+9.93%-27.83%-73.86%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-7.62%-6.02%+73.28%+34.48%-90.21%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
+1.64%-5.34%-30.14%-45.37%-55.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3.00
Buy$5.00362.96% Upside
Imunon, Inc. stock logo
IMNN
Imunon
2.00
Hold$10.00502.41% Upside
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
2.33
Hold$260.00740.61% Upside
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
2.33
Hold$11.00343.55% Upside

Current Analyst Ratings Breakdown

Latest IMNN, RADX, QNCX, and ATNM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$68.00
8/18/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$70.00
8/12/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/29/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/29/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$82.00
7/17/2026
Imunon, Inc. stock logo
IMNN
Imunon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/29/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/24/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
6/24/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$80.00
6/23/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$80.00
(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$35.09M0.97N/AN/A$1.31 per share0.82
Imunon, Inc. stock logo
IMNN
Imunon
N/AN/AN/AN/A$0.35 per shareN/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/A($34.73) per shareN/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$2.35M15.26N/AN/A$3.52 per share0.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M$0.36N/AN/AN/AN/A-100.85%-47.89%N/A
Imunon, Inc. stock logo
IMNN
Imunon
-$14.49M-$3.83N/AN/AN/AN/A-358.01%-132.91%11/12/2026 (Estimated)
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$83.98M-$156.71N/AN/AN/AN/AN/A-133.84%11/11/2026 (Estimated)
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
-$24.83MN/AN/AN/AN/AN/AN/AN/AN/A

Latest IMNN, RADX, QNCX, and ATNM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$28.02-$12.31+$15.71-$12.31N/AN/A
8/11/2026Q2 2026
Imunon, Inc. stock logo
IMNN
Imunon
-$0.8675-$0.54+$0.3275-$0.54N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
Imunon, Inc. stock logo
IMNN
Imunon
N/AN/AN/AN/AN/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/AN/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
Imunon, Inc. stock logo
IMNN
Imunon
2.86
1.82
1.82
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/A
14.52
14.52
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
3.01
N/A

Institutional Ownership

CompanyInstitutional Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
Imunon, Inc. stock logo
IMNN
Imunon
4.47%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
30.75%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A

Insider Ownership

CompanyInsider Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.60%
Imunon, Inc. stock logo
IMNN
Imunon
2.83%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
7.10%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3031.44 million29.32 millionOptionable
Imunon, Inc. stock logo
IMNN
Imunon
305.61 million5.45 millionNot Optionable
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
601.02 million945,000Optionable
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A14.46 millionN/AN/A

Recent News About These Companies

Radiopharm Theranostics (NASDAQ:RADX) Stock Price Down 8.4% - Here's Why
August 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30973662
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348199/0/en/radiopharm-theranostics-receives-positive-recommendation-from-data-safety-and-monitoring-committee-to-advance-to-cohort-4-in-177lu-rad202-phase-1-heat-clinical-trial.html
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/radiopharm-theranostics-meet-u-fda-113000466.html
RADX: RAD101 Topline & FY:26 Cash Flows
August 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/radx-rad101-topline-fy-26-151400375.html
Radiopharm Dips on Securities Pact
July 25, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23725/Radiopharm-Dips-on-Securities-Pact
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
July 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/24/3332785/0/en/radiopharm-theranostics-announces-concurrent-us-4-1-million-registered-direct-offering-and-up-to-additional-a-12-7-us-8-9-million-australian-placement-and-share-purchase-plan.html
Radiopharm Highlights Data Release
July 23, 2026  |  baystreet.cahttps://www.baystreet.ca/techinsider/5668/Radiopharm-Highlights-Data-Release
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331243/0/en/radiopharm-theranostics-achieves-confirmed-durable-partial-response-in-ongoing-phase-1-trial-of-rad204-in-patients-with-advanced-solid-tumors-post-immunotherapy.html
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331214/0/en/radiopharm-theranostics-announces-positive-phase-2b-trial-results-of-rad-101-for-diagnosis-of-brain-metastases.html
Radiopharm Theranostics Ltd ADR RADX
July 16, 2026  |  morningstar.comM
Radiopharm Theranostics Limited Sponsored ADR
May 14, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/RADX
RADX: Fiscal 3Q:26 Cash Flow Report
May 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/radx-fiscal-3q-26-cash-092400408.html
Radiopharm Theranostics Ltd. ADR
May 13, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/radx/financials
Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs
April 28, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/radiopharm-theranostics-adr-radx-inside-the-clinical-programs-1748993/
Radiopharm Theranostics Reports Business Update
April 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/23/3279721/0/en/radiopharm-theranostics-reports-business-update.html
Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer ...
April 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/radiopharm-theranostics-presents-initial-findings-110000207.html
Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
April 16, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/radiopharm-theranostics-completes-enrollment-in-u-s-phase-2b-imaging-trial-of-rad-101-for-diagnosis-of-brain-metastases-1036028670
Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target increased by 752.98% to 39.26
April 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/radiopharm-theranostics-limited-depositary-receipt-radx-price-target-increased-by-752-98-to-39-26/ar-AA20YjrZ
Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target decreased by 11.04% to 4.60
April 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/radiopharm-theranostics-limited-depositary-receipt-radx-price-target-decreased-by-1104-to-460/ar-AA20utAZ
Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
April 8, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/radiopharm-theranostics-advances-to-cohort-3-in-177lu-rad202-phase-1-dose-escalating-clinical-trial-1036002743

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.08 +0.03 (+2.86%)
Closing price 08/25/2026 04:00 PM Eastern
Extended Trading
$1.08 0.00 (0.00%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Imunon stock logo

Imunon NASDAQ:IMNN

$1.66 +0.07 (+4.40%)
Closing price 08/25/2026 04:00 PM Eastern
Extended Trading
$1.63 -0.03 (-1.81%)
As of 05:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Quince Therapeutics stock logo

Quince Therapeutics NASDAQ:QNCX

$30.93 -2.55 (-7.62%)
Closing price 08/25/2026 04:00 PM Eastern
Extended Trading
$28.33 -2.60 (-8.41%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Radiopharm Theranostics stock logo

Radiopharm Theranostics NASDAQ:RADX

$2.48 +0.04 (+1.64%)
Closing price 08/25/2026 03:59 PM Eastern
Extended Trading
$2.40 -0.08 (-3.23%)
As of 08/25/2026 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas